Financial Performance - ZipRecruiter, Inc. reported a quarterly loss of $0.1 per share, better than the Zacks Consensus Estimate of a loss of $0.13, and compared to earnings of $0.07 per share a year ago, representing an earnings surprise of +23.08% [1] - The company posted revenues of $112.23 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.82%, but down from $123.66 million year-over-year [2] - Over the last four quarters, ZipRecruiter has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - ZipRecruiter shares have declined approximately 44.9% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current status of estimate revisions translates into a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.16 on revenues of $112.39 million, and -$0.59 on revenues of $446.17 million for the current fiscal year [7] - The outlook for the industry can significantly impact the stock's performance, with the Business - Services industry currently in the top 40% of Zacks industries [8]

Company Performance - Karyopharm Therapeutics reported a quarterly loss of $4.32 per share, which was worse than the Zacks Consensus Estimate of a loss of $3.8, and compared to a loss of $3 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $37.93 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 5.37%, and down from $42.79 million in the same quarter last year [2] - Over the last four quarters, Karyopharm has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - Karyopharm shares have lost approximately 61.1% since the beginning of the year, contrasting with the S&P 500's gain of 8.6%, indicating significant underperformance in the market [3] - The current consensus EPS estimate for the upcoming quarter is -$3.58 on revenues of $39.87 million, and for the current fiscal year, it is -$12.57 on revenues of $149.93 million [7] Industry Context - The Medical - Drugs industry, to which Karyopharm belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a relatively strong position within the sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Karyopharm's stock performance [5]

Core Viewpoint - Hillenbrand reported quarterly earnings of $0.51 per share, exceeding the Zacks Consensus Estimate of $0.50 per share, but down from $0.85 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was +2.00%, with the company previously expected to post earnings of $0.54 per share but actually delivering $0.60, resulting in a surprise of +11.11% [2] - Hillenbrand's revenues for the quarter ended June 2025 were $598.9 million, surpassing the Zacks Consensus Estimate by 4.63%, compared to $786.6 million in revenues a year ago [3] - The company has consistently exceeded consensus revenue estimates over the last four quarters [3] Stock Performance - Hillenbrand shares have declined approximately 35.9% since the beginning of the year, while the S&P 500 has gained 8.6% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.49 on revenues of $558.9 million, and for the current fiscal year, it is $2.20 on revenues of $2.55 billion [8] - The outlook for the industry can significantly impact the stock's performance, with the Industrial Services sector currently ranking in the top 29% of over 250 Zacks industries [9]

Group 1 - Lincoln Educational Services Corporation (LINC) reported quarterly earnings of $0.09 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, and showing an increase from $0.06 per share a year ago, representing an earnings surprise of +125.00% [1] - The company posted revenues of $116.47 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.99%, and an increase from $102.91 million year-over-year [2] - Lincoln Educational Services has outperformed the S&P 500, with shares increasing about 50.1% since the beginning of the year compared to the S&P 500's gain of 8.6% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $129.27 million, and for the current fiscal year, it is $0.72 on revenues of $490.47 million [7] - The Zacks Industry Rank indicates that the Schools industry is currently in the top 12% of over 250 Zacks industries, suggesting a favorable outlook for companies within this sector [8]

Company Performance - LivePerson reported a quarterly loss of $0.11 per share, better than the Zacks Consensus Estimate of a loss of $0.20, and a significant improvement from a loss of $0.69 per share a year ago, resulting in an earnings surprise of +45.00% [1] - The company posted revenues of $59.6 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.19%, although this represents a decline from year-ago revenues of $79.88 million [2] - Over the last four quarters, LivePerson has exceeded consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - LivePerson shares have declined approximately 20.4% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $57.56 million, and for the current fiscal year, it is -$0.63 on revenues of $240.99 million [7] Industry Outlook - The Internet - Services industry, to which LivePerson belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact LivePerson's stock performance [5]

Core Insights - Myomo, Inc. reported a quarterly loss of $0.11 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.03 per share a year ago [1] - The company achieved revenues of $9.65 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.42%, and up from $7.52 million year-over-year [2] - Myomo shares have declined approximately 71.6% year-to-date, contrasting with the S&P 500's gain of 8.6% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [1] - Myomo has topped consensus revenue estimates four times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $12.83 million, and -$0.16 on revenues of $50.34 million for the current fiscal year [7] Market Outlook - The Zacks Rank for Myomo is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The outlook for the Medical - Products industry, to which Myomo belongs, is currently in the bottom 38% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The correlation between near-term stock movements and earnings estimate revisions is emphasized, indicating that investors should monitor these trends closely [5]

Financial Performance - EuroDry reported a quarterly loss of $1.1 per share, which was better than the Zacks Consensus Estimate of a loss of $1.23, but worse than a loss of $0.17 per share a year ago, indicating a significant decline [1] - The company posted revenues of $11.28 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.09% and down from $17.44 million year-over-year [2] - Over the last four quarters, EuroDry has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - EuroDry shares have declined approximately 9.8% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for EuroDry is 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.90 on revenues of $12.89 million, and for the current fiscal year, it is -$5.12 on revenues of $46.03 million [7] - The trend of estimate revisions for EuroDry was unfavorable prior to the earnings release, which may impact future stock movements [5][6] Industry Context - The Transportation - Shipping industry, to which EuroDry belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, suggesting a challenging environment for stock performance [8] - Empirical research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - 4D Molecular Therapeutics reported a quarterly loss of $0.98 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.88, and compared to a loss of $0.63 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $0.02 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 98.58%, while revenues were zero a year ago [2] - The stock has added about 1.1% since the beginning of the year, underperforming the S&P 500's gain of 8.6% [3] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.93 on revenues of $1.06 million, and for the current fiscal year, it is -$3.45 on revenues of $4.17 million [7] - The estimate revisions trend for 4D Molecular Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which 4D Molecular Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Core Viewpoint - Payoneer Global Inc. (PAYO) has seen a 2.5% increase in share price over the past four weeks, closing at $6.64, with analysts suggesting a potential upside of 44% based on a mean price target of $9.56 [1][11]. Price Targets and Analyst Estimates - The mean estimate for PAYO comprises nine short-term price targets with a standard deviation of $1.67, indicating variability among analysts [2]. - The lowest price target is $7.00, suggesting a 5.4% increase, while the highest target is $12.00, indicating an 80.7% potential increase [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.3%, with two estimates moving higher and no negative revisions [12]. - PAYO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be prudent due to historical inaccuracies in predicting stock movements [3][7]. - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8][10].

Financial Performance - Humacyte, Inc. reported a quarterly loss of $0.24 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, representing an earnings surprise of -60.00% [1] - The company posted revenues of $0.3 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 73.6%, compared to zero revenues a year ago [2] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $3.02 million, and for the current fiscal year, it is -$0.17 on revenues of $8.77 million [7] Stock Performance - Humacyte, Inc. shares have declined approximately 50.9% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The company has surpassed consensus EPS estimates two times over the last four quarters [2] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Humacyte belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Humacyte's stock performance [5]